AVARA Rx vs Revel Health
A code-dependent rate against an introductory month.
AVARA Rx
Editorial
$229/mo
AVARA Rx publishes compounded tirzepatide at $279 a month, or $229 with a discount code, and compounded semaglutide at $229 with no code attached. The provider consult and free shipping are stated as included in both figures, and no insurance is required. A code is a condition rather than a price, so $279 is the tirzepatide figure to budget against.
Pick it for: Readers who can confirm the code before ordering
Revel Health
Editorial
$149/mo
Revel Health advertises compounded semaglutide at $199 a month by injection and $149 as an oral dissolving tablet, with compounded tirzepatide at $249 and $199 on the same pattern. The oral is the cheaper route on both molecules, which reverses the usual order. Each line also carries a reduced first month, and the seller states that consultation, medication, supplies and shipping are included in the rate. Forty-five states.
Pick it for: Readers who want a single figure covering the whole service afterwards
Our verdict
Avara Rx's lower figure is conditional on a code; Revel Health's is conditional on it being the first month. Both are real and neither is the ongoing price.
What actually separates them
AVARA Rx and Revel Health state different things about published price. Everything else they publish, they publish the same way.
AVARA Rx costs $80 more than Revel Health — 54% more for the same molecule. Whether that buys anything is what the rest of this page is for.
Over twelve months that is about $1,788 at Revel Health against $2,748 at AVARA Rx — a difference of $960.
| AVARA Rx | Revel Health | |
|---|---|---|
| Published price | $229/mo | $149/mo |
Before you choose either
Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against every published price we hold rather than against each other alone.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.